Pathological analysis of abnormal activation for peptidylarginine deiminase in brain

脑内肽基精氨酸脱亚胺酶异常激活的病理分析

基本信息

项目摘要

Citrullinated proteins are the products of a post-translational process in which arginine residues undergo modification into citrulline residues when catalyzed by peptidylarginine deiminases (PADs) in a calcium ion-dependent manner. In our previous report, PAD2 expressed mainly in the rat cerebrum became activated early in the neurodegenerative process. To elucidate the involvement of protein citrullination in human neuronal degeneration, we examined whether citrullinated proteins are produced during Alzheimer's disease (AD). By Western blot analysis using anti-modified citrulline antibody, citrullinated proteins of varied molecular weights were detected in hippocampal tissues from patients with AD but not normal humans. Two of the citrullinated proteins were identified as vimentin and glial fibrillary acidic protein (GFAP) by using two-dimensional gel electrophoresis and MALDI-TOF mass spectrometry. Interestingly, PAD2 was detected in hippocampal extracts from AD and normal brains, bu … More t the amount of PAD2 in the AD tissue was markedly greater. Histochemical analysis revealed citrullinated proteins throughout the hippocampus, especially in the dentate gyrus and stratum radiatum of CA1 and CA2 areas. However, no citrullinated proteins were detected in the normal hippocampus. PAD2 immunoreactivity was also ubiquitous throughout both the AD and normal hippocampal areas. PAD2-enrichment coincided well with citrullinated protein-positivity. Double immunofluorescence staining revealed that citrullinated protein- and PAD2-positive cells also coincided with GFAP-positive cells, but not all GFAP-positive cells were positive for PAD2. Like GFAP, which is an astrocyte-specific marker protein, PAD2 is distributed mainly in astrocytes. These collective results, the abnormal accumulation of citrullinated proteins and abnormal activation of PAD2 in hippocampi of patients with AD, strongly suggest that PAD has an important role in the onset and progression of AD and that citrullinated proteins may became a useful marker for human neurodegenerative diseases. Less
瓜氨酸化蛋白是翻译后过程的产物,其中当被肽基精氨酸脱亚胺酶(PAD)以钙离子依赖性方式催化时,精氨酸残基经历修饰成瓜氨酸残基。在我们以前的报告中,PAD 2主要在大鼠大脑中表达,在神经退行性变过程的早期被激活。为了阐明瓜氨酸蛋白参与人类神经元变性,我们研究了瓜氨酸化蛋白是否在阿尔茨海默病(AD)期间产生。通过使用抗修饰瓜氨酸抗体的蛋白质印迹分析,在AD患者的海马组织中检测到不同分子量的瓜氨酸化蛋白,但在正常人中未检测到。通过双向凝胶电泳和MALDI-TOF质谱鉴定了两种瓜氨酸化蛋白,分别为波形蛋白和胶质细胞酸性蛋白(GFAP)。有趣的是,在AD和正常大脑的海马提取物中检测到了PAD 2, ...更多信息 AD组织中PAD 2的量显著增加。组织化学分析表明,瓜氨酸蛋白在整个海马,特别是在齿状回和放射层的CA 1和CA 2区。然而,在正常海马中未检测到瓜氨酸化蛋白。PAD 2免疫反应性也普遍存在于整个AD和正常海马区。PAD 2富集与瓜氨酸化蛋白阳性一致。双重免疫荧光染色显示瓜氨酸蛋白和PAD 2阳性细胞也与GFAP阳性细胞一致,但并非所有GFAP阳性细胞均为PAD 2阳性。与星形胶质细胞特异性标志蛋白GFAP一样,PAD 2主要分布在星形胶质细胞中。这些结果,瓜氨酸化蛋白的异常积累和AD患者大脑中PAD 2的异常激活,强烈表明PAD在AD的发生和发展中具有重要作用,瓜氨酸化蛋白可能成为人类神经退行性疾病的有用标志物。少

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Accelerated tubular cell senescence in SMP30 knockout mice.
  • DOI:
    10.14670/hh-21.1151
  • 发表时间:
    2006-11
  • 期刊:
  • 影响因子:
    2
  • 作者:
    W. Yumura;T. Imasawa;S. Suganuma;A. Ishigami;S. Handa;S. Kubo;K. Joh;N. Maruyama
  • 通讯作者:
    W. Yumura;T. Imasawa;S. Suganuma;A. Ishigami;S. Handa;S. Kubo;K. Joh;N. Maruyama
Senescence marker protein 30 functions as gluconolactonase in L-ascorbic acid biosynthesis, and its knockout mice are prone to scurvy
抗MuSK抗体陽性重症筋無力症の病因と病態
抗MuSK抗体阳性重症肌无力的病因和病理
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    0
  • 作者:
    重本和宏;久保幸穂;丸山直記
  • 通讯作者:
    丸山直記
蛋白質のシトルリン化と病態
蛋白质瓜氨酸化和病理学
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    丸山直記;石神昭人
  • 通讯作者:
    石神昭人
アルツハイマー病でのシトルリン化蛋白質の異常な蓄積
阿尔茨海默病中瓜氨酸蛋白的异常积累
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KUBO Sachiho其他文献

KUBO Sachiho的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KUBO Sachiho', 18)}}的其他基金

Analysis of pathogenic mechanisms of myasthenia gravis.
重症肌无力发病机制分析。
  • 批准号:
    19590374
  • 财政年份:
    2007
  • 资助金额:
    $ 2.3万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似国自然基金

新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
  • 批准号:
    81000622
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
  • 批准号:
    31060293
  • 批准年份:
    2010
  • 资助金额:
    26.0 万元
  • 项目类别:
    地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
  • 批准号:
    30960334
  • 批准年份:
    2009
  • 资助金额:
    22.0 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Using Photobiomodulation to Alleviate Brain Hypoperfusion in Alzheimer's Disease
利用光生物调节缓解阿尔茨海默氏病的大脑灌注不足
  • 批准号:
    10656787
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Discovery and development of apoE4 correctors for the treatment of Alzheimer's disease
发现和开发用于治疗阿尔茨海默病的 apoE4 校正剂
  • 批准号:
    10901029
  • 财政年份:
    2023
  • 资助金额:
    $ 2.3万
  • 项目类别:
Skeletal complications to a TREM2 variant associated with Alzheimer's Disease
与阿尔茨海默病相关的 TREM2 变异的骨骼并发症
  • 批准号:
    10408018
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Alzheimer's Disease associated pathology induced by neurotropic viral infection
嗜神经病毒感染诱发的阿尔茨海默病相关病理
  • 批准号:
    10673912
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Skeletal complications to a TREM2 variant associated with Alzheimer's Disease
与阿尔茨海默病相关的 TREM2 变异的骨骼并发症
  • 批准号:
    10259555
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Skeletal complications to a TREM2 variant associated with Alzheimer's Disease
与阿尔茨海默病相关的 TREM2 变异的骨骼并发症
  • 批准号:
    10618952
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Recovery of Synaptic Dysfunction and Memory Loss in Alzheimer's Disease by Selective Co-Activation of Nicotinic Acetylcholine Receptors
通过烟碱乙酰胆碱受体的选择性共激活恢复阿尔茨海默病的突触功能障碍和记忆丧失
  • 批准号:
    10303598
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Alternative Splicing of ApoER2 in Alzheimer's Disease
阿尔茨海默病中 ApoER2 的选择性剪接
  • 批准号:
    10396990
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Recovery of Synaptic Dysfunction and Memory Loss in Alzheimer's Disease by Selective Co-Activation of Nicotinic Acetylcholine Receptors
通过烟碱乙酰胆碱受体的选择性共激活恢复阿尔茨海默病的突触功能障碍和记忆丧失
  • 批准号:
    10468170
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
Alzheimer's Disease associated pathology induced by neurotropic viral infection
嗜神经病毒感染诱发的阿尔茨海默病相关病理
  • 批准号:
    10381213
  • 财政年份:
    2021
  • 资助金额:
    $ 2.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了